Decheng Capital LLC Lyell Immunopharma, Inc. Transaction History
Decheng Capital LLC
- $573 Billion
- Q3 2025
A detailed history of Decheng Capital LLC transactions in Lyell Immunopharma, Inc. stock. As of the latest transaction made, Decheng Capital LLC holds 595,466 shares of LYEL stock, worth $10.1 Million. This represents 1.69% of its overall portfolio holdings.
Number of Shares
595,466
Previous 595,466
-0.0%
Holding current value
$10.1 Million
Previous $5.26 Billion
83.71%
% of portfolio
1.69%
Previous 1.33%
Shares
2 transactions
Others Institutions Holding LYEL
# of Institutions
9Shares Held
37.4MCall Options Held
0Put Options Held
0-
Apoletto LTD Washington, DC15.1MShares$256 Million42.56% of portfolio
-
Black Rock Inc. New York, NY13.5MShares$228 Million0.0% of portfolio
-
Wu Xi App Tec Co., Ltd. Shanghai, F47.39MShares$125 Million53.56% of portfolio
-
Nuveen Asset Management, LLC Chicago, IL641KShares$10.9 Million0.0% of portfolio
-
Credit Suisse Ag Zurich, V8123KShares$2.09 Million0.0% of portfolio
About Lyell Immunopharma, Inc.
- Ticker LYEL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 247,824,992
- Market Cap $4.2B
- Description
- Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate...